MaxCyte MXCT US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MaxCyte in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about MaxCyte's us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MaxCyte's US — revenue?
- MaxCyte (MXCT) reported US — revenue of $6.62M in Q1 2026.
- How has MaxCyte's US — revenue changed year-over-year?
- MaxCyte's US — revenue decreased by 17.6% year-over-year, from $8.03M to $6.62M.
- What is the long-term trend for MaxCyte's US — revenue?
- Over 2 years (2023 to 2025), MaxCyte's US — revenue has grown at a -19.4% compound annual growth rate (CAGR), from $32.42M to $21.08M.
- What does US — revenue mean?
- This metric represents the total gross income generated from the sale of instruments, consumables, and licensing agreements within the United States geographic market. It serves as a key indicator of the company's market penetration and commercial adoption of its cell engineering platform technology in the domestic region. Tracking this revenue stream helps investors assess the company's ability to capture market share and sustain growth within its primary operating territory.